Pfizer Loses Fight To Persuade NICE Of Xalkori’s Cost-Effectiveness
This article was originally published in The Pink Sheet Daily
Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.
You may also be interested in...
As Global Payers Become Monopolies, Biopharma Need To Demonstrate Value Earlier – AusBiotech Conference
Biopharma companies should define value propositions early and have a case for value differentiation at the discovery stage if they want to make a case to payers.
Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.
Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.